 |
Actelion Pharmaceuticals Ltd (VTX:ATLN) Actelion's First-in-class Selective S1P1 Receptor Agonist To Enter Phase II Clinical Development
NOV 13, 2008 16:03 - Article Views: 364
Actelion Pharmaceuticals Ltd (VTX:ATLN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
|
 |
|
Actelion Pharmaceuticals Ltd (SWF:ATLN) Actelion Announces 9-months Results For 2008
OCT 21, 2008 16:03 - Article Views: 354
Actelion Pharmaceuticals Ltd (SWF:ATLN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Total net revenues of CHF 1,069.6 million, up 21 percent in local currencies and 13 percent in Swiss Francs - Tracleer® sales of CHF 945.8 million, up 21 percent in local currencies and 12 percent in Swiss Francs - Cash EBIT of CHF 355.6 million, up 18 percent in local currencies and 2 percent in Swiss Francs - Strong cash generation enables full funding of maturing pipeline - Upgraded 2008 guidance
|
|
|
Actelion Pharmaceuticals Ltd (SWF:ATLN) Actelion To Discuss Financial 9 Month Results 2008 With Development
pipeline Update
OCT 18, 2008 01:37 - Article Views: 246
Actelion Pharmaceuticals Ltd (SWF:ATLN) Corporate news announcement processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion senior management to host Q & A session.
|
|
|
Actelion Pharmaceuticals Ltd (SWF:ATLN) Actelion Included In The Swiss Market Index SMI
SEP 22, 2008 15:03 - Article Views: 787
Actelion Pharmaceuticals Ltd (SWF:ATLN) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
|
|
|
Tracleer® (bosentan) Receives EU Approval For Treatment Of Patients
With Mildly Symptomatic Pulmonary Arterial Hypertension
AUG 5, 2008 13:41 - Article Views: 328
Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- --------------
|
|
|
Actelion Announces Half Year Financial Results 2008
JULY 22, 2008 15:03 - Article Views: 1,367
Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Total net revenues of CHF 676.0 million - Product sales up 18 percent in local currencies compared to H1 2007 - Tracleer® sales of CHF 605.2 million - Cash EBIT of CHF 190.8 million - Multiple Phase III studies on track - Substantial impact from Actelion/GSK orexin receptor antagonist collaboration to start immediately in H2 2008
|
|
|
Actelion To Discuss Half Year Financial Results 2008
JULY 19, 2008 01:37 - Article Views: 345
Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion senior management to host Q & A session
|
|
|
Actelion And GlaxoSmithKline Enter Into Exclusive Collaboration To
Realise The Full Potential Of Almorexant In Sleep Disorders And
Beyond
JULY 14, 2008 15:09 - Article Views: 1,096
Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion and GlaxoSmithKline (GSK) to potentially co-develop and co-commercialise other orexin receptor antagonists
|
|
|
Invitation To Investor Webcast/Conference Call
JULY 14, 2008 15:09 - Article Views: 216
Actelion Pharmaceuticals Ltd (OTC:ALIOF) Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- Actelion and GlaxoSmithKline enter into exclusive collaboration to realize the full potential of almorexant in sleep disorders and beyond
|
|
